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Abstract: Over recent years stem cells have stood out as a promising tool for regenerative medicine, providing alternative therapeutic
solutions for a large number of diseases. Many clinical trials using stem cells or induced pluripotent stem cells are focused on the repair
and regeneration of various tissues and organs in degenerative diseases, whose current treatment only succeeds in slowing down the
progression of the disease. Although the preliminary results are interesting, further studies are required in order to evaluate the safety
and benefits of stem cell therapy, considering the teratoma development and ethical considerations in embryonic stem cell cases or
reprogramming-induced somatic mutations and epigenetic defects. This review summarizes several current clinical and nonclinical
data on the use of embryonic stem cells, mesenchymal stem cells, and induced pluripotent stem cells in various diseases.
Key words: Regenerative medicine, stem cells, cell reprogramming

1. Introduction
Current treatments for many degenerative diseases such
as Alzheimer and Parkinson disease, motor neuron
disease, multiple sclerosis, diabetes, and kidney, liver,
and heart diseases, as well as for many types of cancer,
are mainly symptomatic, and for certain diseases, total
recovery implies whole organ transplantation (Gieseck et
al., 2015).
Stem cell therapy that concerns cell reprogramming
and transplantation of embryonic stem cells (ESCs),
mesenchymal stem cells (MSCs), and induced pluripotent
stem cells (iPSCs) represents an interesting yet disputed
research area, with exciting results for many diseases.
These pluripotent/multipotent cells can be differentiated
in vitro to a desired cell type and they are used for
transplantation into patients with various disorders, as
illustrated in the Figure. Stem cells, including ESCs and
MSCs, present self-renewal ability and they also have the
capacity to differentiate into one or more mature cellular
lineages, being promising tools for clinical applications.
In the course of mammalian development, stem cells are
involved in tissue and organ formation (ESCs), and in

several adult tissues they can provide regenerative capacity
(adult stem cells). These properties are directed by the
interaction of cell type-specific transcription factors and
chromatin regulators (Klimanskaya et al., 2008; Sarkar and
Hochedlinger, 2013; Mariano et al., 2015).
Gaining knowledge about stem cells has enabled
the development of a new branch of medicine, called
regenerative medicine. In this new branch, the therapeutic
act involves the manipulation of stem cells in order to
regenerate tissues and organs of an organism altered by
destruction, disease, or congenital defects (Katari et al.,
2014; El-Badawy and El-Badri, 2015; McNamara et al.,
2015). A first use of the stem cells has been performed
in bone marrow transplantation containing multipotent
stem cells in patients with various forms of hematological
disorders, including acute myelogenous leukemia, acute
lymphoblastic leukemia, non-Hodgkin lymphoma, and
myelodysplastic syndromes (Karanes et al., 2008). This
review presents several current clinical and nonclinical
data concerning mainly the use of ESCs, MSCs, and iPSCs
in the treatment of different diseases, highlighting both the
opportunities and the limitations of this therapy.
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Figure. The main strategies for generating desired cell types for subsequent
transplantation into patients involve direct differentiation of embryonic stem cells
(ESCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs)
derived from somatic cells by manipulation of several transcription factors (TF) or by
modulation of signaling pathways.

2. Embryonic stem cells
ESCs are stem cells derived from an early stage of embryo
development or from the inner cell mass of the developing
embryo, capable of differentiating into nearly all cell
types of all three germ layers (ectoderm, mesoderm, and
endoderm). Pluripotency characterizes especially the
early stage of embryo development (Mizuno et al., 2012;
Chuang et al., 2015). The ESC capacity of proliferation
and transformation in all somatic cells made these
cells, initially, the main source of stem cells. The use of
ESCs in therapy, although extremely promising, raises
diverse issues such as rejection of ESCs, which requires
immunosuppressive treatment, and the possibility to
induce tumor cells, presenting legal and ethical limitations
(Kfoury, 2007; Ramos-Zuniga et al., 2012; Schwartz et al.,
2012). Thus, in vivo experiments conducted in the areas
of tissue destruction showed that ESC administration to
immunodeficient mice, by injection of these cells into the
wound, did not lead to the restoration of the tissue but
rather to the formation of tumors called teratoma, with a
low malignancy potential, containing structures derived
from all three germ layers. This type of experiment has
shown that the therapeutic use of ESCs necessitates
isolation, cultivation, and forced differentiation in order
for them to derive into the desired cell types. Only these
differentiated cells may be safely injected into the recipient
(Hentze et al., 2009).
Limitations of ESC use are also caused by their
immunological
rejection
phenomena;
therefore,
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appropriate immunosuppressive strategies are required
(Stuckey and Shah, 2014). Clinical trials using ESCs
have focused on several disease treatments, including
neurological (Ambasudhan et al., 2014), cardiac (Ban
et al., 2014), and pancreatic (Wu et al., 2011) disorders,
highlighting the regenerative potential of ESCs for
damaged structures.
In a study that used human ESC-derived cardiomyocytes
in a nonhuman primate model of myocardial ischaemia,
it was shown that the infarcted monkey heart presented
extensive remuscularization after treatment, with nonfatal
ventricular arrhythmias as a secondary effect (Chong et
al., 2014). Hepatocyte-like cells derived from human ESCs
and engrafted into mice sustained proliferation of host
hepatocytes and revascularization of injured host liver tissue
by providing trophic factors involved in liver regeneration,
while human ESC-derived pancreatic progenitor cells can
differentiate in vivo into functional islets in diabetic mice
(Rezania et al., 2012; Woo et al., 2012).
In the United States, two prospective phase 1/2
studies evaluated the safety and tolerability of subretinal
transplantation of human ESC-derived retinal pigment
epithelium in patients with Stargardt macular dystrophy
and atrophic age-related macular degeneration.
The preliminary results suggested that no adverse
proliferation, rejection, or safety issues were associated
with the treatment. Moreover, improvements in subretinal
pigmentation visual acuity have been observed (Schwartz
et al., 2015).
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3. Adult stem cells
MSCs, the commonest type of adult stem cells, represent
an attractive research field for scientists due to their
potential to regenerate damaged or degenerated tissues
and organs, and also because their use does not create
ethical or immunological concerns. MSCs represent
an accessible stem cell source since they can be isolated
from adult somatic tissues, such as the bone marrow, skin,
adipose tissue, umbilical cord, and intestines. These cells,
together with endometrial stem cells, can differentiate into
one or more lineages with mesodermal and ectodermal
origin (hepatocytes, osteoblasts, smooth muscle,
cardiomyocytes, cartilage, adipocytes, pancreatic cells,
neuronal cells, dopaminergic neurons), displaying a high
proliferative potential, clonogenicity, or colony forming
unit activity (Ghobadi et al., 2015; Goodarzi et al., 2015).
MSCs are able to manage the repair response by recruiting
other cells and by secreting several bioactive molecules,
including growth factors and matrix proteins capable of
stimulating the recovery of damaged cells and inhibiting
inflammation. These cells are also characterized by weak
immunogenicity and, at the same time, by the ability
to perform immunomodulatory functions. Although
primary MSCs are found in a limited number in human
tissues, these stem cells can be expanded in long-term
culture systems, allowing the obtainment of a large-scale
production of MSCs for clinical application (Wang et al.,
2011; Wang et al., 2012).
Based on MSCs’ unique properties, such as tissue
repair and major histocompatibility complex (MHC)unmatched immunosuppression, these cells have been
used for graft-versus-host disease (GVHD) treatment, a
major cause of morbidity and mortality after allogeneic
hematopoietic stem cell transplantation. A combination
therapy with MSCs and Treg cells, for example, seems
to increase the immunomodulatory activity of MSCs
(Kitazawa et al., 2012; Lim et al., 2014). Using in vitro
and in vivo experiments, Jang et al. demonstrated that
placenta-derived MSCs transplanted into mice can control
GVHD after hematopoietic stem cell transplantation
(Jang et al., 2013). Clinical data suggest a benefit in
approximately two-thirds of the patients with steroidresistant acute GVHD (Tolar et al., 2011; Resnick
et al., 2013). In systemic sclerosis, a chronic disease
characterized by early activation of the immune system,
MSCs manifest immunomodulatory functions, such as an
immunosuppressive effect on lymphocyte proliferation
(Cipriani et al., 2013). Furthermore, preclinical and clinical
studies have focused on MSC-based therapy in Crohn
disease, a major inflammatory bowel disease characterized
by pathological immune responses to different antigens
(Forte et al., 2015). Clinical studies demonstrated that,
when administered locally by injection, MSCs represent a

harmless therapy that can sustain the therapeutic response
in patients with Crohn disease (Ciccocioppo et al., 2015).
MSCs have been efficiently developed as a promising
tool for clinical applications in digestive tract defects
(Sirbu-Boeti et al., 2009), as well as in musculoskeletal
diseases, including bone fractures, bone defects, focal
chondral lesions, osteoarthritis, spinal diseases, and
tendon injuries (Wei et al., 2014). Recent studies in the
equine industry demonstrated that MSCs have the capacity
to differentiate into osteoblasts by manipulation of several
transcription factors, such as runt-related transcription
factor 2 (Runx2) and osterix (Osx); this therapy can
improve fracture healing and reduce the incidence of
reinjury (Govoni, 2015). In secondary osteoporosis,
systemic transplantation of human bone marrow MSCs
and stem cells from exfoliated deciduous teeth in murine
models recovered the reduction of bone density through
IL-17 suppression (Ma et al., 2015).
Due to the important role of MSCs in bone tissue repair
or regeneration, numerous studies have focused on testing
pharmacological molecules able to promote MSC homing
or to mobilize bone marrow MSCs in the peripheral blood
for enhancing the recruitment of MSCs to the injured
bone tissues (Zhou et al., 2015).
There are also several studies showing that MSCs
can be considered therapeutic tools for patients with
neurodegenerative diseases, including Alzheimer
disease, Parkinson disease, amyotrophic lateral sclerosis,
Huntington disease, and multiple sclerosis, due to their
capacity to transdifferentiate into neural cells and their
neuroprotective and immunomodulatory effects (Tanna
and Sachan, 2014). Genetically modified MSCs were used
in neurodegenerative diseases as vehicles for transporting
or releasing neurotrophic factors, such as glial cell-derived
neurotrophic factor (GDNF), nerve growth factor (NGF),
and brain-derived neurotrophic factor (BDNF), able to
protect and to sustain regeneration of damaged tissue
(Wyse et al., 2014). Even if initially adult neural stem
cells (aNSCs) were considered a promising source for
stem cells in neurodegenerative disorders due to their
capacity to differentiate easily into neuronal lineages,
experiments showed that these stem cells are vulnerable
to immune responses following transplantation. The
results obtained by an in vivo study demonstrated that
transplantation of combined MSCs and aNSCs resulted in
increased survival of the transplanted aNSCs as well as a
longer-term behavioral benefit in a transgenic rat model
of Huntington disease, mainly because MSCs are less
vulnerable to rejection following transplantation and also
due to the fact that MSCs might ensure a more favorable
environment for aNSCs’ survival (Rossignol et al., 2014).
In a rat model of Parkinson disease, MSC transplantation
resulted in upregulation of peripheral antiinflammatory
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cytokines, increased neurogenesis, and improved memory
functioning, with modulatory effects on the hippocampus
(Schwerk et al., 2015).
Neural crest cells represent a multipotent and migratory
cell population able to generate a variety of cell and tissue
types, such as craniofacial cartilage and bone, smooth
muscle, peripheral and enteric neurons, glia, melanocytes,
or connective tissue (Achilleos and Trainor, 2012). Neural
crest progenitors persist in adult life in differentiated
tissues, including the enteric nervous system of the gut,
the hair follicles of the facial skin, etc. (Teng and Labosky,
2006). Although differentiated, the neural crest-derived
cells possess phenotypic plasticity. Dupin et al., using in
vitro experiments, showed that epidermal pigment cells
and Schwann cells from peripheral nerves have the capacity
to reverse into multipotent neural crest-like progenitors
with a self-renewal property. It seems that various neural
crest progenitors can express stem cell properties; at the
same time, differentiated cells of neural crest origin can
reacquire these functions, raising the possibility of using
them as a promising tool for regeneration (Dupin et al.,
2007). Human epidermal neural crest stem cells from the
bulge of hair follicles are also suitable candidates for cellbased therapies, disease modeling, and drug discovery
(Sieber-Blum, 2014).
Recently, a rare population of very small embryoniclike stem cells (VSELs), still under scientific debate, was
identified in a quiescent state in bone marrow and other
adult tissues. They are smaller than red blood cells,
express several markers characteristic for pluripotent
stem cells (Oct 4, Nanong, SSEA), and could be mobilized
in peripheral blood under stress conditions. They are
supposed to be a link between early development stages
and adult stem cell compartments. VSELs hold the promise
of a new source for developing regenerative therapies to
repair complex tissue damaged by trauma or degenerative
conditions, such as osteoporosis (Ratajczak et al., 2012;
Havens et al., 2013; Ratajczak et al., 2014).
Recent but also disputed studies have identified stem
cells in adult mammalian ovaries that can be involved
in oocyte renewal. These ovarian germline stem cells are
well characterized in nonmammalian model organisms
and the perspective of isolation and growth of human
ovarian stem cells could offer new opportunities for the
treatment of women’s infertility (Hanna and Hennebold,
2014). In vivo studies demonstrated that transplantation
of a small proportion of human and mouse cells from
ovarian epithelium and cortical tissue can generate
immature oocytes into ovaries of immunodeficient mice
(Gheorghisan-Galateanu et al., 2014).
Nasal stem cells are multipotent stem cells localized
in the olfactory mucosa, being considered as an attractive
source for autologous stem cell-based therapies due
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to their accessibility. These stem cells are involved in
adult neurogenesis and tissue regeneration after injury;
therefore, several studies focused on the use of nasal stem
cells for biomarker identification in brain disorders or
for repairing processes in the pathological/traumatized
nervous system (Fletcher et al., 2011; Feron et al., 2013;
Stamegna et al., 2014).
Hematopoietic stem cells (HSCs) symbolize the
classical stem cell of the organism. The first clinical use was
in hematological malignancy therapy, aiming to restore
normal hematopoiesis. Nowadays, HSC transplantation is
utilized with increased success rates in various malignant
and nonmalignant conditions. HSCs can be isolated from
bone marrow and umbilical cord blood and they have the
capacity to repopulate the entire hematopoietic system.
HSCs also have the capacity to sustain the regeneration
of nonhematopoietic tissue such as that of the liver, heart,
and brain. More than 2000 clinical studies regarding the
use of HSCs in the treatment of numerous diseases (e.g.,
cancers, leukemia, lymphoma, cardiac failure, neural
disorders, autoimmune diseases, immunodeficiency,
and metabolic or genetic disorders) are currently being
conducted (Chivu-Economescu and Rubach, 2015; Porada
et al., 2015).
4. Human induced pluripotent stem cells
In 2006, a seminal paper (Takahashi and Yamanaka, 2006)
showed, using mouse fibroblasts, that adult somatic cells
could be converted to stem cells. These cells share similar
features to ESCs (morphology, stem cell markers, stem
cell gene expression, self-renewal, and differentiation
potential) and they were designated as iPSCs. The
technology employed by Yamanaka’s team to reprogram
adult cells required simultaneous introduction of four
transcription factor genes (called reprogramming factors),
Oct3/4, Sox2, c-Myc, and Klf4, by means of a retroviral
system. A year later, 2 research groups managed to
independently generate human induced pluripotent stem
cells (hiPSCs) from somatic cells using either the same
approach as in mouse cells –Oct4, Sox2, c-Myc, and Klf4
with a retroviral vector (Takahashi et al., 2007) – or OCT4,
SOX2, NANOG, and LIN28 with a lentiviral system (Yu et
al., 2007).
Although the precise process by which somatic cells
are converted to iPSCs is not fully understood, recent
studies have revealed that the reprogramming factors
Oct3/4, Sox2, and Nanog inhibit genes involved in cell
differentiation, and together with c-Myc determine
epigenetic changes (methylation of DNA, chromatin
modification) that lead to the generation of iPSCs (Loh et
al., 2006; Kim et al., 2008). Moreover, similarly to ESCs,
the promoter regions of Nanog, Oct3/4, and Fbx15 were
demethylated in iPSCs (Takahashi and Yamanaka, 2006;
Miyazaki et al., 2012).
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Since their first description, hiPSCs have received huge
interest not only among scientists but also in the general
population due to their tremendous potential applications
in regenerative medicine, drug development, toxicity tests,
and disease modeling. They overcome the ethical aspects
related to ESC production and represent an endless source
for patient-specific stem cells.
Besides dermal fibroblasts, commonly used as source
for hiPSC generation (Takahashi et al., 2007; Yu et al., 2007;
Raab et al., 2014), a wide variety of cells were employed:
hepatocytes (Liu et al., 2010), keratinocytes (Aasen et al.,
2008), melanocytes (Utikal et al., 2009), astrocytes (Ruiz
et al., 2010), dental pulp cells (Yoo et al., 2013), umbilical
vein endothelial cells (Haile et al., 2015), cord blood
(Haase et al., 2009), peripheral blood mononuclear cells
(Fuerstenau-Sharp et al., 2015), kidney mesangial cells
(Song et al., 2011), exfoliated renal epithelial cells present
in urine (Zhou et al., 2012), etc.
However, though a promising tool for future therapies,
hiPSC technology implies certain challenging hurdles
in terms of safety and efficacy: the risk of insertional
mutagenesis, as well as tumor formation, a low efficiency
rate of conversion, and incomplete reprogramming. In
order to avoid the integration of vector and transgene
sequences into the cell genome, alternate vectors were
used: adenoviral vectors (Zhou and Freed, 2009), Sendai
virus (Fusaki et al., 2009; Chichagova et al., 2016),
episomes (Fontes et al., 2013), plasmids (Okita et al.,
2008), transposons (Kaji et al., 2009; Woltjen et al., 2009),
synthesized mRNAs (Warren et al., 2010), and protein
(Kim et al., 2009).
Direct transfection of human somatic cells with specific
mature microRNA molecules (such as a combination of
mir-200c, -302s, and -369s families (Miyoshi et al., 2011)
or the miR302/367 cluster (Anokye-Danso et al., 2011))
is capable of reprogramming human somatic cells to
pluripotency (Okano et al., 2013).
Recent studies were pursued to generate iPSCs using
combinations of small molecules that could replace either
partially or completely the transcription factors and
improve the efficiency of reprogramming. These small
chemical compounds are epigenetic modifiers, WNT signal
modulators, moderators of cell senescence, modulators of
metabolism, and regulators of MET (Lin and Wu, 2015).
In 2013, Hou et al. described for the first time a cocktail
of small molecules (forskolin, valproic acid, CHIR99021,
616452, tranylcypromine, 3-deazaneplanocin) that are
able to reprogram differentiated cells into iPSCs (Hou et
al., 2013).
iPSCs offer an attractive application in diseasemodeling and drug discovery. To date, many patientspecific iPSC lines have been established and used to create
disease models, and they are expected to facilitate studies

on rare diseases (Bellin et al., 2012). An international
collaborative project, StemBANCC, started in 2012, aims
to generate and characterize 1500 hiPSC lines. The project,
conducted by the University of Oxford and gathering 10
pharmaceutical companies and 23 universities, will offer
researchers valuable resources for a better understanding
of the disease pathogenic mechanisms and the chance to
develop new treatments (http://stembancc.org/).
The ability to differentiate into many cell types, the
relatively easy accessibility, the renewable capacity, and
the possibility to use individual autologous and allogeneic
cells contribute to the therapeutic potential of hiPSCs in
regenerative medicine. In diseases previously considered
incurable, such as neurodegenerative disorders (Ross
and Akimov, 2014; Brandl et al., 2015), spinal cord injury
(Kobayashi et al., 2012; Nakamura and Okano, 2013),
heart failure (Fujita et al., 2012; Hsiao et al., 2013; Khan
et al., 2015), diabetes (Abdelalim et al., 2014; Bose et al.,
2014; Holditch et al., 2014), and retinal disease (Mead et
al., 2015), hiPSC replacement-based therapies represent a
promising approach (Seki and Fukuda, 2015).
The damaged or degenerated tissue is repaired by
means of iPSCs obtained from the patient’s somatic cells,
differentiated in vitro and then transplanted in the affected
tissue. In the case of diseases caused by a genetic mutation,
it is possible to correct the genetic defect by obtaining
mutation-free iPSCs, further to be differentiated to specific
cell types. In a very recent paper, using reprogramming
and editing genome technologies, Crane et al. managed
to correct CFTR gene mutations responsible for cystic
fibrosis in patient-derived iPSCs and restored gene
function (Crane et al., 2015). Another group reported
gene correction of alpha 1 anti-trypsin (A1AT) deficiency,
one of the common genetic disorders associated with liver
disease that might progress to cirrhosis and hepatocellular
carcinoma, as well as with pulmonary emphysema.
Hepatocyte-like cells obtained through differentiation of
iPSCs presented the genetic and phenotypic correction of
the Z mutation, one of the most common mutant forms of
A1AT (Choi et al., 2013).
In 2013, Takebe et al. reported the generation of a
functional human organ from pluripotent stem cells for
the first time. They managed to create a three-dimensional
vascularized and functional human liver using a coculture
of hepatic endoderm cells derived from human iPSCs,
human umbilical vein endothelial cells, and human MSCs.
iPSC-derived liver buds transplanted into mice generated
a vascularized and functional human liver. Although
there are many steps to be done before their application in
clinical medicine, these findings open a promising path in
regenerative medicine (Takebe et al., 2013).
The first clinical trial using hiPSCs received the
approval of the Japanese Ministry of Health and started
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in Japan in 2014; the study addresses people suffering
from wet age-related macular degeneration, a disease
that may lead to blindness in aged people. The study
employs autologous iPSCs derived from the patient’s
skin that are differentiated to retinal pigment epithelial
cells and transplanted into the affected retina (Reardon
and Cyranoski, 2014). Nevertheless, several studies have
demonstrated that during in vitro culture, reprogrammed
cells can accumulate genomic instability and genomic
abnormalities, including de novo mutations that are not
identified in human ESCs. Although the consequences
of these epigenetic and genetic alterations are not well
known, the affected cells seem to acquire premalignant
properties, such as decreased differentiation and increased
proliferative capacity. These observations support the
necessity of controlling the hiPSCs’ genome integrity
before any clinical application (Puri and Nagy, 2012;
Nguyen et al., 2013).
5. Cell signaling pathway modulation promotes somatic
cell reprogramming
Stem cells are involved in tissue development, renewal,
and regeneration, activities sustained by the ‘niche’, a local
stem cell microenvironment. On the other hand, stem
cells can generate their own niche, using several signaling
pathways crucial for stem cell maintenance (Clevers
et al., 2014). An important resource for regenerative
medicine is the reprogramming of mature somatic cells
to become pluripotent by the manipulation of several
factor expressions. Trying to understand and improve
the molecular mechanisms of induced pluripotency,
cell signaling pathways that control the reprogramming
process have also been extensively studied, including LIF/
STAT3, PI3K/Akt, Wnt/β-catenin, TGFβ, and MAPK
cascades (Kim et al., 2011; Hawkins et al., 2014).
In order to reprogram somatic cell, SamavarchiTehrani et al. used a secondary mouse embryonic fibroblast
model to obtain iPSCs by manipulating Oct4, Klf4, c-Myc,
and Sox2 expressions. Based on the results obtained by
temporal gene expression analysis, they suggested that
somatic cell reprogramming is a multistep process that
includes initiation, maturation, and stabilization phases
(Samavarchi-Tehrani et al., 2010).
The initiation phase of reprogramming is characterized
by loss of the somatic cell program (e.g., loss of the
transcription factors Snail1/2 or Zeb1/2 and gain of an
epithelial signature by increased expression of CDH1,
EpCAM, or the epithelial-associated miRNA family),
metabolism changes, increased proliferation rate,
inhibition of apoptosis and senescence, and morphologic
changes (e.g., fibroblasts undergo a mesenchymal-toepithelial transition, MET) (David and Polo, 2014). The
epigenetic regulators have a significant role in the initiation
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phase; using mouse embryonic fibroblasts deleted in all
three TET genes, Hu et al. observed that this model failed
to initiate the reprogramming, mainly because TETs are
involved in miR-200 activation and MET, respectively (Hu
et al., 2014). The maturation phase is characterized by a
major transcriptional modification, the gain of a subset
of pluripotency associated genes (Nanog, Oct4, Esrrb,
ICAM1), while the stabilization phase includes transgeneindependent self-renewal, pluripotency, loss of epigenetic
memory, x-reactivation, and telomerase elongation,
presenting as specific markers Sox2, Dppa4, and PECAM
(David and Polo, 2014).
Recent studies demonstrated that modulation of Wnt/
β-catenin, MAPK/ERK, TGF-β, or PI3K/Akt signaling
pathways enhances somatic-cell reprogramming (Sanges
and Cosma, 2010).
The Wnt/β-catenin signaling pathway comprises Wnt
ligands, Frizzled receptors, and a complex composed
of APC (adenomatous polyposis coli), Axin1, GSK-3β
(glycogen synthase kinase 3-β), and CK1 (casein kinase
1) that stabilizes β-catenin (Amado et al., 2014). Several
studies demonstrated the critical role of Wnt signaling in
self-renewal and maintenance of stem cells, and also in
somatic-cell reprogramming. Marson et al. showed that
Wnt cascade activation by soluble Wnt3a can directly
sustain the induction of pluripotency, even in the absence
of c-Myc transduction (Marson et al., 2008). In a recent
study, Aulicino et al. demonstrated that in the early
reprogramming phases of mouse embryonic fibroblasts
into iPSCs, Wnt signaling must be downregulated,
while in the late reprogramming phases an activation of
this signaling is required in order to obtain an efficient
reprogramming (Aulicino et al., 2014). These results are
supported by another study showing that Wnt signaling,
through its transcriptional factors Tcf1, Lef1, Tcf3, and
Tcf4, can inhibit the early stage of reprogramming to
iPSCs (Ho et al., 2013). An in vitro study showed that
blocking nuclear localization of β-catenin by upregulation
of E-cadherin (inhibitor of Wnt signaling) sustains the
epiblast stem cells’ reprogramming to ESCs (Murayama et
al., 2015).
The TGF-β cascade is another critical signaling
pathway for somatic-cell reprogramming. Several studies
demonstrated that Sox2, Oct4, and c-Myc factors sustain
MET by suppression of Snail and TGF-β1/TGF-βR2
(epithelial-to-mesenchymal transition activators), while
the Klf4 factor directly sustains MET by E-cadherin
activation. Thus, TGF-β signaling inhibition has a crucial
role in both early and late events of somatic cell transition
to a pluripotent state (Li et al., 2010; Samavarchi-Tehrani
et al., 2010; Vidal et al., 2014). Yuan et al. reported that
a TGF-β receptor inhibitor, A-83-01, in combination
with a protein arginine methyltransferase inhibitor, AMI-
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5, sustained the reprogramming of mouse embryonic
fibroblasts transduced with only Oct4 factor (Yuan et
al., 2011). Primordial germ cell reprogramming into a
pluripotent state is carried out by downregulation of
TGF-β and ERK (extracellular signal-regulated kinase)
signaling pathways, using specific inhibitors (Attari et al.,
2014).
The JAK-STAT3 cascade is one of the most significant
signaling pathways for the maintenance of mouse ESC
pluripotency and propagation, by activation of c-Myc
transcription and stabilization of c-Myc protein levels;
moreover, it has been demonstrated that Klf4 expression
is induced by JAK-STAT3 signaling activation, depending
on LIF signaling (Tang and Tian, 2013). LIF/STAT3
signaling is crucial for the maturation phase of mouse
iPSCs’ reprogramming by suppression of DNMT1 (DNA
methyltransferase) and histone deacetylases 2, 3, and 8,
with the final result of demethylation of pluripotencyassociated gene promoters (Hawkins et al., 2014).
PI3K/Akt signaling activation was identified in the
initiation phase, being involved in the metabolic switch
from oxidative phosphorylation to glycolysis by activation
of glycolytic regulators AS1060 and PFKB2 (Chen et al.,
2012; Hawkins et al., 2014). Zhu et al. demonstrated that
Akt activation is capable of increasing reprogramming by
upregulation of glycolytic genes (Zhu et al., 2010).
Cell signaling pathways modulated by extrinsic factors
and an intrinsic transcriptional network control the
somatic cell reprogramming and the use of small molecule
modulators of these signaling pathways can induce
reprogramming with greater efficiency, substituting for
classical transcription factors (Ma et al., 2013; David and
Polo, 2014).
6. Biomimetic scaffolds and stem cells
Stem cell therapy in regenerative medicine involves the use
of different strategies for in vitro construction of threedimensional tissues or organs. Usually these approaches
combine diverse scaffolds and signaling systems, thus
inducing the differentiation of stem cells. Biomimetic
scaffolds are made of natural or synthetic polymers or
natural/synthetic hybrids. Natural polymers-collagen
(Ott et al., 2008), fibrin (Christman et al., 2004), alginate
(Landa et al., 2008), Matrigel (Giraud et al., 2008), chitosan
(Lu et al., 2009), and hyaluronic acid (Holloway et al.,
2015) are biodegradable proteins or polysaccharides that
have a structure similar to the native components of the
extracellular matrix, making them biocompatible and less
immunogenic than synthetic polymers. They also have a
higher capacity for cell adhesion and influence on various
cellular functions. Disadvantages of such natural polymerbased scaffolds reside in the limited mechanical properties
and biodegradability.

Skin and oral mucosa were generated on a micronized
acellular dermal matrix (micronized Alloderm), using a
combination of keratinocytes and adipose tissue stem cells
(hASCs) (Yoo and Lim, 2009), as well as on other matrixes
(Fang et al., 2014). The same cells (hASCs) were used on
advanced collagen scaffolds with regular architecture,
generating in vivo neovascularization and adipocyte
differentiation (von Heimburg et al., 2003; Hemmrich et
al., 2005).
In cardiac repair, some promising results were related
to the use of collagen scaffolds, reported to enhance the
survival of cardiomyoblasts and improve survival of
ischemic rats (Miki et al., 2012). Injection of biomimetic
scaffolds at the site of myocardial infarction (eventually
supplemented with bioactive molecules) is reported to
decrease the amount of fibrosis and ventricular dilation
and to promote angiogenesis and recruitment of native
stem cells (Kutschka et al., 2006; Zamora et al., 2013).
Bone reconstruction using scaffolds like hydroxyapatite,
hydroxyapatite gel, or calcium phosphate was reported
in bone reconstruction using bone marrow stromal cells
(Özdal-Kurt et al., 2015); a similar approach was reported
for the regeneration of dental pulp (Ravindran and George,
2015). The use of stem cells in neural differentiation/
neuroregeneration was also reported, such as for induction
of motor neuron differentiation applied with complex
matrices that included collagen grafted nanofibers (Bagher
et al., 2015), or peripheral nerve repair with single-walled
carbon nanotubes/poly-lactic acid scaffolds (Kabiri et al.,
2015).
Combination of multiple cell types, like hepatocytes and
MSCs, with acellular matrixes for organ reconstruction is
another field with promising results (Kadota et al., 2014).
7. Conclusions
Induced pluripotent stem cells together with embryonic
stem cells and adult stem cells represent important
candidates for regenerative medicine due to their extensive
self-renewal and pluripotent proprieties. Stem cells have
been tested for use in several diseases such as spinal
cord injury, heart disease, stroke, and Parkinson disease,
and also in various forms of hematological disorders.
Nevertheless, the therapeutic use of stem cells is currently
limited by several issues such as ethical considerations,
teratoma development, and the long-term possibility
of carcinogenesis, somatic mutations, and epigenetic
defects induced by reprogramming. Further preclinical
and clinical studies are needed in order to determine
whether stem cell-based therapies can be useful in treating
disorders for which available current treatments only
succeed in slowing down the progression of the disease.
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